David Fischel Net Worth

David Fischel biography

David L. Fischel CPA serves as Chairman of the Board, Chief Executive Officer of the Company. He was named chief executive officer and chairman of the board effective as of February 3, 2017. He has served as a director of Stereotaxis since leading the equity investment and positive strategic initiatives announced in September 2016. He has served for over ten years as Principal and portfolio manager for medical device investments at DAFNA Capital Management, LLC. In addition to his research responsibilities, Mr. Fischel has been deeply involved in all aspects of DAFNA Capital’s operations including legal, accounting, IT, compliance, human resources and marketing. Prior to joining DAFNA Capital, he was a research analyst at SCP Vitalife, a healthcare venture capital fund. Mr. Fischel completed his B.S. magna cum laude in Applied Mathematics with a minor in Accounting at the University of California at Los Angeles and received his MBA from Bar-Ilan University in Tel Aviv. He is a Certified Public Accountant, Chartered Financial Analyst and Chartered Alternative Investment Analyst. Mr. Fischel’s financial experience and understanding of the medical device industry enables him to make valuable contributions to our strategic initiatives and general management matters.

What is the salary of David Fischel?

As the Chairman of the Board e Chief Executive Officer of Stereotaxis, the total compensation of David Fischel at Stereotaxis is $240,300. There are no executives at Stereotaxis getting paid more.

How old is David Fischel?

David Fischel is 33, he's been the Chairman of the Board e Chief Executive Officer of Stereotaxis since 2017. There are 8 older and no younger executives at Stereotaxis. The oldest executive at Stereotaxis, Inc. is Robert Messey, 74, who is the Independent Director.

What's David Fischel's mailing address?

David's mailing address filed with the SEC is 4320 Forest Park Ave, St. Louis, MO 63108, USA.

Insiders trading at Stereotaxis

Over the last 6 years, insiders at Stereotaxis have traded over $16,447,723 worth of Stereotaxis stock and bought 502,585 units worth $872,120 . The most active insiders traders include Joe E Kiani, Paul J Isaac, eMyriam Curet. On average, Stereotaxis executives and independent directors trade stock every 39 days with the average trade being worth of $124,591. The most recent stock trade was executed by Paul J Isaac on 28 May 2024, trading 1,254 units of STXS stock currently worth $2,358.

What does Stereotaxis do?

Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.

Stereotaxis executives and stock owners

Stereotaxis executives and other stock owners filed with the SEC include:

• Ross Levin,
  Independent Director
• Robert Messey,
  Independent Director
• Arun Menawat,
  Independent Director
• Joseph Kiani,
  Independent Director
• David Benfer,
  Lead Independent Director
• Nathan Fischel,
  Director
• David Fischel,
  Chairman of the Board, Chief Executive Officer
• Kimberly R. Peery,
  Chief Financial Officer
• Kimberly Peery,
  Chief Financial Officer
• Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A., CFA, CPA,
  CEO & Chairman
• Guy Judkowski,
  Equity Portfolio Mang.
• Joe E Kiani,
  Director
• Paul J Isaac,
  Director
• Kevin M. Barry,
  Chief Legal Officer & Secretar
• Martin C Stammer,
  Chief Financial Officer
• Myriam Curet,
  Director